Back to Authors

Moriarty, Kelsey

https://orcid.org/0000-0002-4350-7931

Mayo Clinic

The University of Texas Southwestern Medical Center

Citations 1

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Altman, Jessica K. , Bixby, Dale L. , Fathi, Amir T. , Foran, James M. , Gojo, Ivana , Hall, Aric C. , Maness, Lori J., Mangan, James K. , Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey , Ali, Moaath K. Mustafa , Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Percival, Mary-Elizabeth, Perl, Alexander E. , Rao, Dinesh S. , Shallis, Rory M. , Shami, Paul J. , Stein, Eytan M. , Stone, Richard M. , Sweet, Kendra , Uy, Geoffrey L. , Vachhani, Pankit , Cassara, Carly J., Freedman-Cass, Deborah A., Stehman, Katie, Uy, Geoffrey , Pollyea, Daniel Aaron , Jonas, Brian A. , Kishtagari, Ashwin , Lancet, Jeffrey E. , Mims, Alice S , Przespolewski, Amanda , Ravandi, Farhad , Thota, Swapna

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 503-513

10.6004/jnccn.2023.0025 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.